Outlook Therapeutics' Lytenava is the first ophthalmic formulation of bevacizumab to be cleared for use by NICE for use in the NHS for wet AMD.

Find the latest Ophthalmology news articles, videos, podcasts, and meeting coverage from medical experts and key opinion leaders you trust.

Background and purpose The Pipeline Embolization Device (PED) has been shown to effectively treat complex internal carotid artery aneurysms while maintaining patency of covered side branches. The ...